Biohit OyjLTS:0DRP -2.95%78 EBITDA Margin % is 26.51% as of Dec. 2025, which is 132% above its 10-year median of 11.41. GuruFocus rates LTS:0DRP with a GF Score™ of 78/100 and a GF Value™ of €2.69 (Fairly Valued). The stock has 4 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Biohit Oyj ranks better than 82.6% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Biohit Oyj's EBITDA for the
six
months ended in Dec. 2025 was €2.20 Mil. Biohit Oyj's Revenue for the
six
months ended in Dec. 2025 was €8.30 Mil. Therefore, Biohit Oyj's EBITDA margin for the quarter that ended in Dec. 2025 was 26.51%.
Biohit Oyj (LTS:0DRP) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Biohit Oyj EBITDA Margin % Related Terms
Biohit Oyj EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Biohit Oyj's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0DRP vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Biohit Oyj's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biohit Oyj EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Biohit Oyj's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Biohit Oyj's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biohit Oyj (LTS:0DRP) has a EBITDA Margin % of 26.51% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Biohit Oyj and its competitors. This is 132% above median its historical median of 11.41. According to the industry distribution chart, Biohit Oyj ranks #142 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 17.4%.
Is Biohit Oyj's EBITDA Margin % too high?
Biohit Oyj's current EBITDA Margin % of 26.51% is 132% above median its 10-year median of 11.41. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Biohit Oyj's value of 26.51% is 254.6% above this industry median. Based on the distribution chart, Biohit Oyj ranks #142 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Biohit Oyj has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biohit Oyj's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Biohit Oyj ranks #142 out of 816 companies for EBITDA Margin %. This places Biohit Oyj in the top 17% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.48. Biohit Oyj's value of 26.51% is 254.6% above this benchmark. While the company's 10-year median is 11.41 vs. the industry median of 7.48, Biohit Oyj has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biohit Oyj's current EBITDA Margin % of 26.51% is 254.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Biohit Oyj and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biohit Oyj's current EBITDA Margin % is 26.51%, which is 132% above median its own 10-year median of 11.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biohit Oyj stock overvalued right now?
Based on GuruFocus' analysis, Biohit Oyj (LTS:0DRP) is currently considered Fairly Valued. The stock's GF Value™ is €2.69, compared to a current price of €2.47 — trading 8.4% below its estimated fair value. The current EBITDA Margin % is 26.51%, which is 132% above median its 10-year median of 11.41 and 254.6% above the Medical Devices & Instruments industry median of 7.48. Biohit Oyj's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Biohit Oyj (LTS:0DRP), the current EBITDA Margin % is 26.51% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biohit Oyj (LTS:0DRP) Overvalued in 2026?
Based on GuruFocus' analysis, Biohit Oyj stock appears to be undervalued.
The current stock price of €2.47 is trading 8.4% below its estimated GF Value™ of €2.69.
GuruFocus considers Biohit Oyj to be Fairly Valued.
Key valuation signals for LTS:0DRP:
EBITDA Margin %: 26.51% (132% above median its 10-year median of 11.41)
GF Value™: €2.69 vs. price of €2.47 (8.4% below fair value)
Industry Position: 254.6% above the Medical Devices & Instruments median (#142 of 816)
No single metric tells the full story. See the LTS:0DRP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biohit Oyj is a globally operating Finnish biotechnology company that develops diagnostic and other health products. Its products include GastroPanel quick test assesses the structure and function of the stomach lining; ColonView quick test is an immunochemical fecal occult blood test (FIT) developed; Acetium capsules protect the stomach lining from carcinogenic acetaldehyde, especially in people with acid-free stomachs. The company's product portfolio consists of diagnostic tests, analysis systems, products binding carcinogenic acetaldehyde into a harmless compound and monoclonal antibodies.
78GF Score
Get the complete analysis for LTS:0DRP
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0DRP has been successfully added to your 
